| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3275763 | Médecine des Maladies Métaboliques | 2010 | 7 Pages |
Abstract
Clinical studies in diabetic patients with albuminuria or diabetic nephropathy at high cardiovascular risk, with drugs acting on renin-angiotensin system (RAS) : angiotensin-converting-enzyme inhibitors (ACEI), or angiotensin II receptor blockers (ARB), indicate dissociated effects on renal and cardiovascular diseases' prevention and/or progression, independent of blood pressure reduction : renal protective effect with daily low doses, but daily higher doses needed to observe a cardiovascular protective effect. These trials support that a strong RAS blockade is needed to achieve not only a renal protective effect but also a cardiovascular preventive/protective effect. Therefore, use of a daily high dose is recommended, either with an ACEI or an ARB, and is preferable to the association of daily low dose of these two therapeutic classes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
M. Marre, J.-P. Sauvanet,